Anti-DLL4 antibodies and methods using same
AssigneeGenentech, Inc.
InventorsMinhong Yan, Yan Wu
Life of this patent
Estimating the term…
Abstract
The invention provides anti-DLL4 antibodies, and compositions comprising and methods of using these antibodies.
Claims19
An isolated anti-DLL4 antibody comprising six hypervariable region (HVR) sequences:
- (i) HVR-L1 comprising sequence A1-A11, wherein A1-A11 is RASQDVSTAVA (SEQ ID NO:
- 10)
- (ii) HVR-L2 comprising sequence B1-B7, wherein B1-B7 is SASFLYS (SEQ ID NO:I 1)
- (iii) HVR-L3 comprising sequence C1-C9, wherein C1-C9 is QQSYTGTVT (SEQ ID NO:
- 18)
- (iv) HVR-H1 comprising sequence D1-D10, wherein D1-D10 is GFTFTDNWIS (SEQ ID NO:
- 1);
- (v) HVR-H2 comprising sequence E1-E18, wherein E1-E18 is GYISPNSGFTYYADSVKG (SEQ ID NO:8) and
- (vi) HVR-H3 comprising sequence F1-F15, wherein F1-F15 is VYYCARDNFGGYFDY (SEQ ID NO:9).
An isolated anti-DLL4 antibody comprising six hypervariable region (HVR) sequences:
- (i) HVR-L1 comprising sequence A1-A11, wherein A1-A11 is RASQDVSTAVA (SEQ ID NO:
- 10)
- (ii) HVR-L2 comprising sequence B1-B7, wherein B1-B7 is SASFLYS (SEQ ID NO:11)
- (iii) HVR-L3 comprising sequence C1-C9, wherein C1-C9 is QQSYNGPST (SEQ ID NO:15)
- (iv) HVR-H1 comprising sequence D1-D10, wherein D1-D10 is GFTFTDNWIS (SEQ ID NO:1)
- (v) HVR-H2 comprising sequence E1-E18, wherein E1-E18 is GVINPNSGATEYADSVKG (SEQ ID NO:5) and
- (vi) HVR-H3 comprising sequence F1-F15, wherein F1-F15 is VYYCARDNFGGYFDY (SEQ ID NO:9).
An isolated anti-DLL4 antibody comprising six hypervariable region (HVR) sequences, wherein the antibody comprises HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3, wherein each, in order, comprises SEQ ID NO:10, 11, 14, 2, 3, and 9.
An isolated anti-DLL4 antibody comprising six hypervariable region (HVR) sequences, wherein the antibody comprises HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3, wherein each, in order, comprises SEQ ID NO:10, 11, 15, 1, 5, and 9.
An isolated anti-DLL4 antibody comprising six hypervariable region (HVR) sequences, wherein the antibody comprises HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3, wherein each, in order, comprises SEQ ID NO:10, 11, 16, 1, 6, and 9.
An isolated anti-DLL4 antibody comprising six hypervariable region (HVR) sequences, wherein the antibody comprises HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3, wherein each, in order, comprises SEQ ID NO:10, 11, 17, 1, 7, and 9.
An isolated anti-DLL4 antibody comprising six hypervariable region (HVR) sequences, wherein the antibody comprises HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3, wherein each, in order, comprises SEQ ID NO:10, 11, 18, 1, 8, and 9.
Dependencies are inferred from the claim text.